Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.30
▼(-55.07% Downside)
Action:ReiteratedDate:03/03/26
The score is primarily weighed down by weak financial performance (steep revenue decline, ongoing losses, and negative operating/free cash flow). Technicals also remain bearish with the price below key moving averages, while oversold readings provide only a modest offset. Valuation is hard to support because the negative P/E reflects unprofitable operations and no dividend data is available.
Positive Factors
Low Leverage
A very low debt-to-equity ratio (0.021) gives the company durable financial flexibility, lowering default and refinancing risk. This supports continued R&D and commercialization spending without large interest burdens, preserving strategic optionality over the next 2-6 months.
Negative Factors
Steep Revenue Decline
A ~72% revenue collapse signals loss of customers, lower test volumes or commercialization setbacks. Such structural top-line deterioration undermines scale economics, lengthens the runway to break-even and makes investment in commercialization riskier over months ahead.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A very low debt-to-equity ratio (0.021) gives the company durable financial flexibility, lowering default and refinancing risk. This supports continued R&D and commercialization spending without large interest burdens, preserving strategic optionality over the next 2-6 months.
Read all positive factors
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$47.90M
Dividend YieldN/A
Average Volume (3M)426.90K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth7.65%
EPS Growth-19.13%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding165,184,000
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.43Price Target Upside-35.82% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Company Description
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis a...
How the Company Makes Money
PIQ generates revenue through several key streams, including contract research services for pharmaceutical and biotechnology companies, which involve bespoke proteomic analyses and biomarker validations. Additionally, the company offers diagnostic...
Proteomics International Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 480.45K | 960.39K | 892.14K | 730.34K | 1.49M | 1.31M |
| Gross Profit | -9.26M | 960.39K | -1.12M | -1.62M | -568.62K | 497.08K |
| EBITDA | -11.94M | -10.00M | -8.40M | -7.55M | -4.56M | -2.77M |
| Net Income | -9.66M | -8.11M | -6.38M | -6.23M | -4.97M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 11.30M | 14.78M | 10.88M | 10.08M | 5.40M | 8.60M |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 11.04M | 6.64M | 6.03M | 2.11M | 5.60M |
| Total Debt | 681.45K | 277.74K | 316.39K | 64.09K | 0.00 | 69.05K |
| Total Liabilities | 4.09M | 1.81M | 1.63M | 1.75M | 2.00M | 990.19K |
| Stockholders Equity | 7.45M | 13.17M | 9.41M | 8.38M | 3.39M | 7.61M |
Cash Flow | ||||||
| Free Cash Flow | -8.41M | -6.63M | -6.00M | -6.91M | -3.67M | -2.41M |
| Operating Cash Flow | -6.35M | -6.60M | -5.59M | -5.69M | -3.54M | -2.21M |
| Investing Cash Flow | -2.07M | -29.65K | -388.02K | -1.17M | -129.46K | -191.00K |
| Financing Cash Flow | 10.76M | 11.03M | 6.59M | 10.77M | 176.10K | 5.64M |
Proteomics International Laboratories Ltd. Technical Analysis
Negative
0.67
Price Trends
0.44
Negative
0.45
Negative
0.41
Negative
Market Momentum
-0.03
Negative
29.48
Positive
23.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PIQ, the sentiment is Negative. The current price of 0.67 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.44, and above the 200-day MA of 0.41, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 29.48 is Positive, neither overbought nor oversold. The STOCH value of 23.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PIQ.
Proteomics International Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$70.88M | -0.82 | -93.08% | ― | 1114.27% | 85.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$57.36M | -4.29 | -254.33% | ― | ― | ― | |
41 Neutral | AU$47.90M | -4.45 | -93.66% | ― | 7.65% | -19.13% | |
41 Neutral | AU$133.02M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:PIQ
Proteomics International Laboratories Ltd.
0.29
-0.22
-43.14%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
10.42%
AU:NUZ
Pharmaust Limited
0.08
-0.05
-37.01%
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-28.57%
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.12
33.43%
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Widens Half-Year Loss as Revenue Declines
Feb 24, 2026
Proteomics International Laboratories reported a weak first half for the six months to 31 December 2025, with operating and other activity revenues falling 30% to $357,000 and total income including grants and other revenue declining 10% to $868,7...
Proteomics International Founder Dr Richard Lipscombe Retires from Board
Feb 23, 2026
Proteomics International Laboratories Ltd announced the formal retirement of founder and Managing Director Dr Richard Lipscombe from its board of directors, effective 23 February 2026, after 25 years of leadership. His departure marks the end of a...
Proteomics International Seeks ASX Quotation for Additional 67,566 Shares
Feb 2, 2026
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 67,566 new fully paid ordinary shares under its code PIQ, with an issue date of 2 February 2026. The additional securities arise from the exercise or conversion of e...
Proteomics International Seeks ASX Quotation for 1.16m New Shares
Jan 21, 2026
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 1,164,320 new ordinary fully paid shares, to be issued on 21 January 2026 under its ticker PIQ. The additional securities, arising from the exercise or conversion of...
Proteomics International Appoints David Morris to Board With No Initial Shareholding
Jan 19, 2026
Proteomics International Laboratories Ltd has appointed David Morris as a director effective 19 January 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Morris currently holds no relevant...
Proteomics International Wins Canadian Patent for PromarkerEso Esophageal Cancer Test
Jan 15, 2026
Proteomics International Laboratories has secured a Canadian patent for PromarkerEso, its first-in-class blood test designed for the early diagnosis of esophageal adenocarcinoma, extending intellectual property protection for the test in Canada un...
Proteomics International Seeks ASX Quotation for 147,286 New Shares
Jan 15, 2026
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 147,286 new fully paid ordinary shares under its ticker PIQ, effective 16 January 2026. The incremental issuance modestly expands the company’s listed share ca...
Proteomics International Names David Morris CEO to Lead Global Commercial Push
Jan 13, 2026
Proteomics International Laboratories has appointed David Morris as Chief Executive Officer and Managing Director, effective 19 January 2026, marking a leadership transition from founder Dr Richard Lipscombe, who retires after 25 years but will as...
Proteomics International Seeks ASX Quotation for Additional 32,430 Shares
Jan 12, 2026
Proteomics International Laboratories Ltd has lodged an application with the ASX for quotation of 32,430 new ordinary fully paid shares under the code PIQ. The additional securities arise from the exercise or conversion of existing options or othe...
Proteomics International Announces Lapse of 15,072 Employee Performance Rights
Jan 9, 2026
Proteomics International Laboratories Ltd has notified the market that 15,072 employee performance rights (ASX code: PIQAY) have lapsed as of 31 December 2025 because the conditions attached to those rights were not met or became incapable of bein...
Proteomics International Wins CAP Accreditation, Commissions US Mass Spec Lab for Promarker Tests
Dec 24, 2025
Proteomics International Laboratories has strengthened its US footprint after its Irvine, California reference laboratory secured accreditation from the College of American Pathologists, a quality benchmark regarded as the gold standard and more d...
PromarkerD Test Enhances Diabetic Kidney Disease Management in Australia
Dec 15, 2025
Proteomics International Laboratories Ltd announced the publication of a peer-reviewed study in the Internal Medicine Journal, demonstrating the clinical utility of their PromarkerD test in Australia. The study showed that PromarkerD significantly...
Proteomics International Launches Precision Diagnostics Services
Dec 12, 2025
Proteomics International Laboratories Ltd has announced the commercial launch of its precision diagnostics services, marking a significant milestone in the company’s operations. This move is expected to enhance the company’s market pos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.